Corline Biomedical AB CLBIO
Updated: 9 Aug 2026
No signal published yet
We already track Corline Biomedical and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Corline Biomedical AB? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Corline Biomedical free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 2, 2026, Corline Biomedical reported five-year follow-up results supporting safety and indicating a positive treatment effect for Renaparin® in kidney transplantation. Previously, on May 8, 2026, the company published its first-quarter 2026 interim report showing net sales of SEK 4.3 million from commercial shipments. During the first quarter, the company's financial position was also strengthened through a directed share issue and a loan from Kardium.
What Firelda Watch includes for Corline Biomedical AB
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Corline Biomedical AB? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Corline Biomedical free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more